



# Financial Tear Sheet

## Corporate Profile

Nabriva is developing its lead product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. We are developing both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP) and intend to develop lefamulin for additional indications other than pneumonia.

## Lefamulin

Nabriva's lead pleuromutilin product candidate, lefamulin, is being studied for the treatment of moderate to severe CABP. We have completed the LEAP 1 Phase 3 trial ...

## Share Performance

Last	Change (%)	Volume	Open
9.79 USD	▼ -0.02 -(0.20%)	11,250	9.91

## Recent News

09/28/17

[Nabriva Therapeutics to Present Lefamulin Data at ID Week 2017](#)

09/20/17

[Nabriva Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference](#)

09/19/17

[Nabriva Therapeutics Announces Pricing of Public Offering of Ordinary Shares of Approximately \\$80 Million](#)

## Upcoming Events

There are currently no events scheduled.

## SEC Filings

Filing Date	Form
10/10/17	SC 13G/A
09/29/17	4
09/26/17	4

## Management

<a href="#">Colin Broom</a>	Chief Executive Officer
<a href="#">Robert Crotty</a>	General Counsel
<a href="#">Steven Gelone</a>	Chief Scientific Officer and Head of Business Development

---

<a href="#">Francesco Maria Lavino</a>	Chief Commercial Officer
<a href="#">Gary Sender</a>	Chief Financial Officer
<a href="#">David Garrett</a>	Vice President, Corporate Controller and Head of Investor Relations
<a href="#">Leanne Gasink</a>	Vice President, Clinical Research and Development
<a href="#">Werner Heilmayer</a>	Vice President CMC & IP
<a href="#">Ernie Kelly</a>	Vice President Quality
<a href="#">Thomas Lembck</a>	Chief Information Officer
<a href="#">William Sargent</a>	Vice President, Commercial Strategy and Access

---

Data provided by Nasdaq. Minimum 15 minutes delayed.